Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
From July, 1980, to June, 1983, 319 patients with newly diagnosed metastatic prostatic cancer were randomized to one of three treatment protocols: diethylstilbestrol (DES) or bilateral orchiectomy, cyclophosphamide plus 5-fluorouracil plus DES, and estramustine phosphate (Emcyt). Ninety-three per cent of 296 patients were eligible for evaluation. This report shows no difference in survival, disease-free progression time, or status regarding pain at entry. Other prognostic factors failed to reveal any difference within any of the treatment protocols.
D001792:Blood Platelets / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000494:pharmacology / Q000627:therapeutic use*; D004961:Estramustine / Q000494:pharmacology / Q000627:therapeutic use*; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011897:Random Allocation
D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D004054:Diethylstilbestrol; D003520:Cyclophosphamide; D005472:Fluorouracil